Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.
{"title":"Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.","authors":"Yujiro Nagata, Takaomi Sugi, Sohei Yamamura, Yoshihiro Sugita, Yui Mizushima, Takuo Matsukawa, Tomohisa Takaba, Kazumasa Jojima, Katsuyoshi Higashijima, Masahiro Matsumoto, Akinori Minato, Ikko Tomisaki, Eiji Kashiwagi, Naohiro Fujimoto","doi":"10.21873/invivo.14016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Currently, there are no established predictive or prognostic biomarkers for first-line enzalutamide (ENZ) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). This multicenter study aimed to assess the predictive and prognostic significance of the initial-to-nadir prostate-specific antigen (PSA) ratio (I/N PSA) during primary androgen-deprivation therapy for <i>de novo</i> metastatic castration-sensitive prostate cancer in relation to the response to first-line ENZ in mCRPC.</p><p><strong>Patients and methods: </strong>A total of 33 patients with mCRPC receiving first-line enzalutamide were included in the study to investigate the correlation between I/N PSA in combined androgen blockade and clinical outcomes. Patients were dichotomized by median I/N PSA values. A PSA response was defined as a 90% or greater decline in PSA levels following the initiation of ENZ treatment in patients with mCRPC.</p><p><strong>Results: </strong>The median I/N PSA was 382. In the high I/N PSA (≥382) group, the PSA response rate was 75.0%, significantly higher than that in the low I/N PSA group (35.3%; <i>p</i>=0.037). The median overall survival following ENZ treatment was significantly better in the high I/N PSA group than in the low group (<i>p</i>≤0.01). Multivariable analysis demonstrated I/N PSA as an independent predictor of overall survival (hazard ratio=0.20; <i>p</i>≤0.01).</p><p><strong>Conclusion: </strong>In patients with mCRPC, the I/N PSA is a promising predictive and prognostic biomarker for first-line ENZ treatment and may provide personalized approaches in daily practice.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2209-2218"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Currently, there are no established predictive or prognostic biomarkers for first-line enzalutamide (ENZ) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). This multicenter study aimed to assess the predictive and prognostic significance of the initial-to-nadir prostate-specific antigen (PSA) ratio (I/N PSA) during primary androgen-deprivation therapy for de novo metastatic castration-sensitive prostate cancer in relation to the response to first-line ENZ in mCRPC.
Patients and methods: A total of 33 patients with mCRPC receiving first-line enzalutamide were included in the study to investigate the correlation between I/N PSA in combined androgen blockade and clinical outcomes. Patients were dichotomized by median I/N PSA values. A PSA response was defined as a 90% or greater decline in PSA levels following the initiation of ENZ treatment in patients with mCRPC.
Results: The median I/N PSA was 382. In the high I/N PSA (≥382) group, the PSA response rate was 75.0%, significantly higher than that in the low I/N PSA group (35.3%; p=0.037). The median overall survival following ENZ treatment was significantly better in the high I/N PSA group than in the low group (p≤0.01). Multivariable analysis demonstrated I/N PSA as an independent predictor of overall survival (hazard ratio=0.20; p≤0.01).
Conclusion: In patients with mCRPC, the I/N PSA is a promising predictive and prognostic biomarker for first-line ENZ treatment and may provide personalized approaches in daily practice.
期刊介绍:
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.